Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study.
Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, Elders PJM, Rauh SP, Jones AG, Holl RW, Stingl JC, Franks PW, McCarthy MI, 't Hart LM, Pearson ER; IMI DIRECT Consortium. Dawed AY, et al. Among authors: jones ag. Diabetes Care. 2019 Jun;42(6):1027-1033. doi: 10.2337/dc18-2182. Epub 2019 Mar 18. Diabetes Care. 2019. PMID: 30885951
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N; DIRECT consortium group. Preiss D, et al. Among authors: jones ag. Diabetes Obes Metab. 2017 Mar;19(3):356-363. doi: 10.1111/dom.12826. Epub 2016 Dec 28. Diabetes Obes Metab. 2017. PMID: 27862873 Free PMC article. Clinical Trial.
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.
Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium. Dennis JM, et al. Among authors: jones ag. Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31. Diabetes Care. 2018. PMID: 29386249 Free PMC article.
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium. Dennis JM, et al. Among authors: jones ag. Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2. Diabetes Care. 2018. PMID: 30072404 Free PMC article.
A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy.
Grubb AL, McDonald TJ, Rutters F, Donnelly LA, Hattersley AT, Oram RA, Palmer CNA, van der Heijden AA, Carr F, Elders PJM, Weedon MN, Slieker RC, 't Hart LM, Pearson ER, Shields BM, Jones AG. Grubb AL, et al. Among authors: jones ag. Diabetes Care. 2019 Feb;42(2):208-214. doi: 10.2337/dc18-0431. Epub 2018 Oct 23. Diabetes Care. 2019. PMID: 30352895 Free PMC article.
Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.
Dennis JM, Henley WE, McGovern AP, Farmer AJ, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, Jones AG; MASTERMIND consortium. Dennis JM, et al. Among authors: jones ag. Diabetes Obes Metab. 2019 Jul;21(7):1576-1584. doi: 10.1111/dom.13687. Epub 2019 Apr 4. Diabetes Obes Metab. 2019. PMID: 30828962 Free PMC article.
364 results